Enterprise Value
747.9M
Cash
265M
Avg Qtr Burn
-37.52M
Short % of Float
12.75%
Insider Ownership
8.41%
Institutional Own.
83.86%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zenocutuzumab (MCLA-128 ) (ADCC) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma, Castration-resistant prostate cancer | Phase 1/2 Data readout | |
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) + Keytruda Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma | Phase 1/2 Data readout | |
MCLA-129 (EGFR x c-MET Biclonics®) + osimertinib Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
MCLA-145 (CD137 x PD-L1 Biclonics®) + Keytruda Details Cancer, Solid tumor/s | Phase 1 Interim update |